|
 |
|
| |
Message From The Company |
|
|
|
A Message from The Medicines Company
The Medicines Company meets the demands of the world's most advanced medical practitioners by commercializing products to improve acute care. The Company markets ANGIOMAX(R) (bivalirudin), an anticoagulant currently approved in the US and other countries for use in patients undergoing coronary angioplasty procedures. The Medicines Company builds value using a wide range of clinical and commercial skills to develop products acquired from leading life science innovators. |
|
| Our Most Recent Webcast |
 |
| SYMBOL |
EVENT TITLE |
LISTEN |
DATE |
TIME (ET) |
| MDCO |
Q1 2013 The Medicines Company Earnings Conference Call |
 |
24-Apr-13 |
8:30 AM |
|
| Our Most Recent Annual Report |
|
|
